Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAOB | P27338 | 20/20 | 1.00 |
| ▸ | MAOA | P21397 | 19/20 | 1.00 |
| ▸ | NPC1 | O15118 | 1/20 | 0.60 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.60 |
| ▸ | HPGD | P15428 | 1/20 | 0.60 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.60 |
| ▸ | GRM5 | P41594 | 1/20 | 0.60 |
| ▸ | RAB9A | P51151 | 1/20 | 0.60 |
| ▸ | NFKB2 | Q00653 | 1/20 | 0.60 |
| ▸ | RELA | Q04206 | 1/20 | 0.60 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.60 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.60 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3451690 | 0.97 | MAOB (0.94) | MAOBMAOANPC1ALDH1A1HPGD | |
| SCHEMBL21297626 | 0.94 | MAOB (0.88) | MAOBMAOANPC1ALDH1A1HPGD | |
| SCHEMBL327001 | 0.91 | MAOB (0.84) | MAOBMAOANPC1ALDH1A1HPGD | |
| SCHEMBL3501723 | 0.89 | MAOB (1.00) | MAOBMAOANPC1ALDH1A1HPGD | |
| SCHEMBL30067289 | 0.89 | MAOB (1.00) | MAOBMAOANPC1ALDH1A1HPGD | |
| SCHEMBL4095412 | 0.87 | MAOA (0.77) | MAOBMAOA | |
| SCHEMBL15839887 | 0.86 | MAOB (1.00) | MAOBMAOA | |
| SCHEMBL22517158 | 0.86 | MAOB (1.00) | MAOBMAOA | |
| SCHEMBL20572760 | 0.86 | MAOB (1.00) | MAOBMAOA | |
| SCHEMBL22517159 | 0.86 | MAOB (1.00) | MAOBMAOA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 177 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-116917280-B | Tetrahydronaphthalene compound, preparation method thereof and application thereof in medicine | 江苏恒瑞医药股份有限公司 | 2026-05-12 | — | — | CN | disclosed |
| US-20260098027-A1 | PHARMACEUTICALLY ACCEPTABLE SALT AND CRYSTAL FORM OF TETRAHYDRONAPHTHALENE DERIVATIVE, AND PREPARATION METHOD | JIANGSU HENGRUI PHARMACEUTICALS CO LTD (CN) | 2026-04-09 | — | — | US | disclosed |
| US-12558428-B2 | Heterobifunctional compounds and their use in treating disease | HALDA THERAPEUTICS OPCO, INC. (US) | 2026-02-24 | — | — | US | disclosed |
| US-20260028354-A1 | TETRAHYDRONAPHTHALENE DERIVATIVES AS ESTROGEN RECEPTOR DEGRADERS | REGENT OF THE UNIV OF MICHIGAN (US) | 2026-01-29 | — | — | US | disclosed |
| US-20250388565-A1 | ESTROGEN RECEPTOR ALPHA DEGRADERS AND METHODS OF USE THEREOF | RELAY THERAPEUTICS, INC. | 2025-12-25 | — | — | US | disclosed |
| US-20250320195-A1 | TETRAHYDRONAPHTHALENE AND TETRAHYDROISOQUINOLINE DERIVATIVES AS ESTROGEN RECEPTOR DEGRADERS | ARVINAS OPERATIONS INC (US) | 2025-10-16 | — | — | US | disclosed |
| US-20250281623-A1 | HETEROBIFUNCTIONAL COMPOUNDS AND THEIR USE IN TREATING DISEASE | HALDA THERAPEUTICS OPCO, INC. | 2025-09-11 | — | — | US | disclosed |
| EP-4596538-A1 | PHARMACEUTICALLY ACCEPTABLE SALT AND CRYSTAL FORM OF TETRAHYDRONAPHTHALENE DERIVATIVE, AND PREPARATION METHOD | Jiangsu Hengrui Pharmaceuticals Co., Ltd. (CN) | 2025-08-06 | — | — | EP | disclosed |
| WO-2025123007-A1 | RAS INHIBITORS AND METHODS OF USE THEREOF | KESTREL THERAPEUTICS INC. (US) | 2025-06-12 | — | — | WO | disclosed |
| CN-120035586-A | Pharmaceutically acceptable salts and crystal forms of tetrahydronaphthalene derivatives and preparation method thereof | 江苏恒瑞医药股份有限公司 | 2025-05-23 | — | — | CN | disclosed |
| US-5504104-A | TREATING INFECTIONS OR DISEASES CAUSED BY RETROVIRUSES, SUCH AS HIV AND AIDS | WARNER-LAMBERT COMPANY (US) | 1996-04-02 | — | — | US | disclosed |
| US-5385947-A | For prevention of nerve damage due to reduction of blood or oxygen supplies | HOFFMANN-LA ROCHE INC. (US) | 1995-01-31 | — | — | US | disclosed |
| EP-0606661-A1 | Octahydrophenanthrene derivatives and their use as NMDA-Antagonists | F. HOFFMANN-LA ROCHE AG (CH) | 1994-07-20 | — | — | EP | disclosed |
| EP-0522000-A1 | 5-LIPOXYGENASE INHIBITORS | SMITHKLINE BEECHAM CORPORATION (US) | 1993-01-13 | — | — | EP | disclosed |
| EP-0284359-B1 | 1,4-DISUBSTITUTED PIPERAZINE COMPOUNDS, THEIR PRODUCTION AND USE | Takeda Chemical Industries, Ltd. (JP) | 1992-01-08 | — | — | EP | disclosed |
| WO-1991014674-A2 | 5-LIPOXYGENASE INHIBITORS | SMITHKLINE BEECHAM CORPORATION (US) | 1991-10-03 | — | — | WO | disclosed |
| US-4880809-A | HYPOTENSIVE AGENTS, AMIDE DERIVATIVES | TAKEDA CHEMICAL INDUSTRIES, LTD. (JP) | 1989-11-14 | — | — | US | disclosed |
| EP-0284359-A1 | 1,4-Disubstituted piperazine compounds, their production and use | Takeda Chemical Industries, Ltd. (JP) | 1988-09-28 | — | — | EP | disclosed |
| US-4420480-A | PARKINSONISM, DEPRESSION, HYPOTENSIVES | MERCK & CO., INC. (US) | 1983-12-13 | — | — | US | disclosed |
| EP-0080115-A2 | Hexahydronaphth(1,2-b)-1,4-oxazines, process for their preparation and pharmaceutical formulation containing them | MERCK & CO. INC. (US) | 1983-06-01 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260098027-A1 | PHARMACEUTICALLY ACCEPTABLE SALT AND CRYSTAL FORM OF TETRAHYDRONAPHTHALENE DERIVATIVE, AND PREPARATION METHOD | MDH2, MDH1, GOT1 | MAOB 4519/4885MAOA 4697/4885NPC1 1277/4885 |
| US-20250388565-A1 | ESTROGEN RECEPTOR ALPHA DEGRADERS AND METHODS OF USE THEREOF | ESRRA, ESRRB, ESR2 | MAOB 958/4885MAOA 841/4885NPC1 1388/4885 |
| US-12558428-B2 | Heterobifunctional compounds and their use in treating disease | BRCA1, H1-0, FOXM1 | MAOB 234/4885MAOA 738/4885NPC1 118/4885 |
| US-20250281623-A1 | HETEROBIFUNCTIONAL COMPOUNDS AND THEIR USE IN TREATING DISEASE | VHL, HMBS, BRCA1 | MAOB 165/4885MAOA 597/4885NPC1 903/4885 |
| US-20260028354-A1 | TETRAHYDRONAPHTHALENE DERIVATIVES AS ESTROGEN RECEPTOR DEGRADERS | ESRRA, ESR2, ESRRB | MAOB 384/4885MAOA 715/4885NPC1 714/4885 |
| US-20250320195-A1 | TETRAHYDRONAPHTHALENE AND TETRAHYDROISOQUINOLINE DERIVATIVES AS ESTROGEN RECEPTOR DEGRADERS | MDM2, CRBN, VHL | MAOB 3417/4885MAOA 3116/4885NPC1 3706/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.